Janssen And Sanofi Keep Mum On EU Fast-Track Request Outcomes
Have Teclistamab And Nirsevimab Made The Grade For Speedy Review At The EMA?
Teclistamab and nirsevimab may or not be fast-tracked when their sponsors – Janssen-Cilag and Sanofi, respectively – file for pan-EU approval. In the meantime, a total of seven filings are currently benefiting from the accelerated assessment mechanism at the European Medicines Agency.
